Episode Details

Johnson & Johnson’s blockbuster drug Stelara just fell off a 62% cliff, but the healthcare giant's portfolio still managed to post double-digit operational growth in Q1 2026.

In ~10 minutes:

• Why GAAP net income dropped 52% on a phantom talc accounting reversal.

• Defending Shockwave's cardiovascular monopoly with an aggressive Gen-5 product pivot.

• How tariffs and massive front-loaded U.S. manufacturing investments squeezed cash flow.

• Trial data proving the Impella heart pump adds 600 days of life.

Despite a 55% plunge in free cash flow, JNJ's aggressive commercial pipeline—highlighted by a staggering 24-hour launch for their new psoriasis pill—has the company firmly on track to eclipse the historic $100 billion annual revenue mark, even as macro tariffs and Chinese pricing controls loom on the horizon. 🧬

Johnson & Johnson (JNJ) | Q1 FY2026

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.